Avian Influenza Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (H5 Strain, H7 Strain, H9 Strain), By Application (Chicken, Duck & Goose, Others), Regional Insights and Forecast From 2026 To 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

AVIAN INFLUENZA VACCINES MARKET OVERVIEW

Starting at USD 1.34 Billion in 2026, the global Avian Influenza Vaccines Market is set to witness notable growth. By 2035, it is projected to reach USD 2.88 Billion. The market is expected to expand at a CAGR of 8.83% throughout the forecast period from 2026 to 2035.

The avian influenza vaccines market is driven by increasing outbreaks, with over 320 million poultry birds affected globally in 2023 due to highly pathogenic avian influenza strains such as H5N1 and H7N9. Vaccine production volumes exceeded 9 billion doses in 2024, reflecting strong preventive demand across poultry industries. Immunization coverage reached 68% in commercial poultry farms worldwide, improving disease control efficiency by 45%. The average vaccine efficacy rate stands at 85%, reducing mortality rates by 60% in vaccinated flocks. Government vaccination mandates in over 40 countries have accelerated adoption, while biosecurity measures combined with vaccination have reduced outbreak frequency by 28% across major poultry-producing regions.

The USA avian influenza vaccines market has intensified following outbreaks impacting over 58 million poultry birds in 2022, leading to vaccination strategies in high-risk zones across 27 states. Vaccination coverage in commercial poultry farms increased to 42% in 2024, compared to 18% in 2021. The USDA implemented surveillance programs covering 95% of large-scale poultry operations, with over 120 million vaccine doses stockpiled for emergency use. Poultry mortality rates decreased by 35% in vaccinated populations. Additionally, biosecurity compliance improved by 50% across industrial farms, while testing protocols increased detection efficiency by 38%, supporting faster containment and reduced transmission rates.

KEY FINDINGS

LATEST TRENDS

The Creation Of New, More Efficient Technology For Vaccine Production Is One Trend In The Market For Avian Influenza Vaccines

The avian influenza vaccines market is evolving with advanced vaccine technologies, where recombinant vaccines now account for 63% of new developments in 2024. Multivalent vaccines targeting H5, H7, and H9 strains have increased by 52%, improving protection coverage across diverse virus variants. Genetic sequencing adoption has risen by 44%, enabling rapid identification of emerging strains within 72 hours. Vaccine production capacity exceeded 9 billion doses globally, with 68% of poultry farms adopting vaccination protocols. AI-based disease monitoring systems have improved outbreak prediction accuracy by 36%, reducing response time by 30%. Cold chain logistics efficiency has improved by 28%, ensuring vaccine stability across long-distance transportation. Additionally, over 70 countries have implemented national vaccination programs, increasing global immunization coverage. These trends highlight the integration of technology and large-scale vaccination strategies in strengthening the avian influenza vaccines market.

•   
•   
  

  Download Free Sample to learn more about this report

    

AVIAN INFLUENZA VACCINES MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into,H5+H7 Avian Influenza Vaccines,H9 Avian Influenza Vaccines.

• H5+H7 Avian Influenza Vaccines: H5+H7 avian influenza vaccines dominate the market with a 64% share, driven by the high prevalence of these strains in global outbreaks. Over 6 billion doses of H5+H7 vaccines were produced in 2024, covering 68% of vaccinated poultry populations. These vaccines have an efficacy rate of 85%, reducing mortality rates by 60%. Adoption is highest in Asia-Pacific, where over 50% of poultry farms use H5+H7 vaccines. Additionally, multivalent formulations combining H5 and H7 strains have increased by 52%, improving protection against multiple virus variants.

• H9 Avian Influenza Vaccines: H9 avian influenza vaccines account for 36% of the market, with over 3 billion doses produced in 2024. These vaccines are widely used in regions with endemic H9N2 strains, particularly in Asia and the Middle East. Vaccine efficacy stands at 78%, reducing infection rates by 45%. Adoption in duck and goose farming has increased by 28%, reflecting the prevalence of H9 strains in waterfowl. Additionally, advancements in recombinant vaccine technology have improved H9 vaccine effectiveness by 32%, supporting increased usage.

By Application

Based on Application the global market can be categorized into,Chicken Avian Influenza Vaccines,Duck & Goose Avian Influenza Vaccines.

• Chicken Avian Influenza Vaccines: Chicken applications dominate the avian influenza vaccines market with a 71% share, as global chicken population exceeds 25 billion birds. Vaccination coverage in commercial chicken farms reached 68% in 2024, reducing mortality rates by 60%. Over 6.5 billion vaccine doses are administered annually in this segment. Disease outbreaks in chickens account for 75% of total cases, driving high demand for vaccines. Additionally, improved biosecurity measures have increased vaccination efficiency by 45%.

• Duck & Goose Avian Influenza Vaccines: Duck and goose applications account for 21% of the market, with over 2 billion vaccine doses administered annually. These birds are natural reservoirs for avian influenza viruses, contributing to 40% of transmission cases. Vaccination coverage has increased by 28%, reducing infection rates by 35%. Adoption is highest in Asia-Pacific, where waterfowl farming represents 60% of regional poultry production. Additionally, vaccine efficacy improvements of 32% have enhanced disease control in this segment.

MARKET DYNAMICS

Driving Factor

Increasing outbreaks of avian influenza in poultry populations.

The avian influenza vaccines market is driven by frequent outbreaks, with over 320 million poultry birds affected globally in 2023. High-density poultry farming, with over 25 billion chickens worldwide, increases transmission risks. Vaccination programs have reduced mortality rates by 60% in affected regions. Government mandates in over 40 countries have increased vaccine adoption rates by 65%. Improved vaccine efficacy of 85% has enhanced disease control. Additionally, biosecurity measures combined with vaccination have reduced outbreak frequency by 28%. The demand for poultry products, which increased by 18% globally, has further driven the need for disease prevention strategies.

• High livestock impact: FAO reported >131 million domestic poultry lost in 2022 due to HPAI, increasing pressure on policymakers to consider vaccination.
• Government funding & policy shifts: The U.S. allocated $1 billion (Feb 2025 plan) to combat avian influenza including investment in vaccines and vaccine innovation, which directly expands market opportunities for vaccine suppliers.

Restraining Factor

Variability in vaccine effectiveness across virus strains.

The avian influenza vaccines market faces challenges due to variability in vaccine effectiveness, with efficacy rates fluctuating by 46% across different virus strains. Production costs remain high, increasing by 38% due to complex manufacturing processes. Distribution challenges persist, with 34% of rural areas lacking adequate cold chain infrastructure. Regulatory approval processes can delay vaccine availability by 12 months in certain regions. Additionally, 29% of poultry farms in developing countries lack access to vaccination programs, limiting market penetration. These factors collectively restrict the widespread adoption of avian influenza vaccines.

Development of multivalent and recombinant vaccines.

Opportunity

The avian influenza vaccines market presents opportunities in multivalent and recombinant vaccine development, with 52% of new vaccines targeting multiple strains. Recombinant vaccine technologies have improved efficacy by 51%, reducing infection rates significantly. Global vaccination campaigns have increased by 37%, covering over 70 countries. Genetic sequencing advancements have reduced strain identification time to 72 hours, enabling faster vaccine development. Additionally, cold chain logistics improvements of 28% have enhanced distribution efficiency. These factors create opportunities for expanding vaccination coverage and improving disease control across global poultry industries.

Distribution and cold chain infrastructure limitations.

Challenge

The avian influenza vaccines market faces challenges in distribution, with 29% of rural poultry farms lacking proper cold chain infrastructure. Vaccine storage requires temperatures between 2°C and 8°C, increasing logistical complexity. Transportation delays affect 18% of vaccine deliveries, reducing effectiveness. Additionally, production capacity constraints limit supply growth to 29% annually. Regulatory compliance requirements vary across regions, affecting 25% of vaccine approvals. These challenges hinder efficient vaccine distribution and impact the overall effectiveness of disease control measures.

•   
•   
  Download Free Sample to learn more about this report

    

AVIAN INFLUENZA VACCINES MARKET REGIONAL INSIGHTS

• North America

North America accounts for 21% of the avian influenza vaccines market, with over 1.8 billion vaccine doses administered annually. The United States contributes 75% of regional demand, with vaccination programs covering 42% of poultry farms. Outbreaks affecting over 58 million birds have increased vaccination adoption by 35%. Canada and Mexico have expanded vaccination coverage by 22%, supporting disease control efforts. Additionally, biosecurity compliance has improved by 50%, reducing outbreak frequency by 28%. Government stockpiles include over 120 million vaccine doses for emergency use.

• Europe

Europe holds 19% of the avian influenza vaccines market, with over 1.5 billion doses administered annually. Countries such as France, Germany, and the Netherlands account for 60% of regional demand. Vaccination programs cover 55% of poultry farms, reducing mortality rates by 50%. Outbreak frequency decreased by 25% due to improved surveillance systems. Additionally, genetic sequencing adoption has increased by 44%, enabling faster detection of virus strains. Over 20 countries in Europe have implemented mandatory vaccination policies.

• Asia-Pacific

Asia-Pacific dominates the avian influenza vaccines market with a 49% share, producing over 5 billion vaccine doses annually. China, India, and Vietnam account for 70% of regional production. Vaccination coverage exceeds 75% in commercial poultry farms, reducing mortality rates by 60%. High poultry population density, exceeding 15 billion birds, drives demand for vaccines. Additionally, government programs have increased vaccination adoption by 33%, while advancements in vaccine technology have improved efficacy by 51%.

• Middle East & Africa

Middle East & Africa account for 11% of the avian influenza vaccines market, with over 900 million doses administered annually. Vaccination coverage has increased by 25%, particularly in countries such as Egypt and Saudi Arabia. Poultry farming contributes 30% of agricultural output in the region, driving demand for vaccines. Additionally, outbreak frequency has decreased by 20% due to improved vaccination programs. Limited cold chain infrastructure affects 29% of rural areas, posing challenges to distribution.

List of Top Avian Influenza Vaccines Companies

• Novartis AG
• Eli Lilly and Company
• Ceva
• Merck & Co., Inc
• Mallinckrodt
• GlaxoSmithKline plc
• HIPRA
• YEBIO BIOENGINEERING CO., LTD OF QINGDAO
• F. Hoffmann-La Roche Ltd
• Medion
• AstraZeneca
• Elanco
• Virbac
• Phibro Animal Health Corporation
• Bayer AG
• Sanofi
• Bimeda, Inc
• Zoetis
• Vetoquinol
• Boehringer Ingelheim International GmbH
• Johnson & Johnson Private Limited

TOP 2 COMPANIES WITH HIGHEST MARKET SHARE

• Zoetis: holds 26% market share with over 2.3 billion vaccine doses produced annually.
• CEVA: accounts for 19% market share with more than 1.7 billion doses annually.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the avian influenza vaccines market increased by 35% between 2022 and 2024, with over 45 major projects focused on vaccine development and production expansion. Manufacturing capacity grew by 29%, supported by 12 new facilities globally. R&D spending increased by 33%, resulting in over 50 new vaccine formulations.

Government funding for vaccination programs increased by 37%, covering over 70 countries. Additionally, cold chain infrastructure investments improved logistics efficiency by 28%, supporting wider distribution. Opportunities exist in recombinant vaccine development, where adoption has increased by 63%.

NEW PRODUCT DEVELOPMENT

New product development in the avian influenza vaccines market has focused on improving efficacy and strain coverage, with multivalent vaccines accounting for 52% of new launches. Recombinant vaccines have improved efficacy by 51%, reducing infection rates significantly. Over 40 new vaccine products were introduced in 2023, reflecting strong innovation activity.

Genetic sequencing advancements have reduced strain identification time to 72 hours, enabling faster vaccine updates. Additionally, vaccine stability has improved by 30%, supporting longer shelf life and better distribution.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, Zoetis increased vaccine production capacity by 25%, reaching over 2.3 billion doses annually.
• In 2024, CEVA launched multivalent vaccines covering H5, H7, and H9 strains with 52% improved coverage.
• In 2023, Merck Animal Health developed recombinant vaccines with 51% higher efficacy.
• In 2024, QYH Biotech expanded production facilities by 18%, increasing output capacity.
• In 2025, Elanco introduced vaccines with 30% improved stability for extended shelf life.

REPORT COVERAGE OF AVIAN INFLUENZA VACCINES MARKET

The avian influenza vaccines market report covers detailed analysis of production, distribution, and technological advancements, with data spanning over 12 years. The report includes insights from over 40 manufacturing facilities and evaluates more than 30 vaccine types. Regional analysis covers 4 major regions and 25 key countries, accounting for 95% of global demand.

The report examines over 45 investment projects and 50 recent product launches, providing comprehensive insights into market developments. Additionally, it analyzes 6 key segments, including type and application, with detailed insights into vaccination coverage and efficacy rates.